SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Lab misses out "first -day launch" of hypertension drug: Report

25 Sep 2012 Evaluate

Country’s largest drug-maker, Ranbaxy Laboratories, has missed out on the 'first -day launch' of its generic version of Novartis' best-seller hypertension drug Diovan in the US, as the company is yet to get the US food and Drug Administration's (FDA's) approval for the generic version of the drug, Valsartan, as mentioned in a media report. The company was scheduled to launch its drug on September 21, 2012, the day from when Diovan's patent expired.

The company has the exclusive rights to market the generic for 180 days, after emerging as the first company to successfully challenge Novartis' patent for Diovan. However, Sandoz, the generic arm of Novartis, unveiled Diovan HCT, its low-cost version of a combination of valsartan and hydrochlorothiazide with a licence from Novartis. Similarly, Mylan Inc too started selling the same low-cost combination drug, also on Friday.

Ranbaxy Laboratories, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1858.10
Dr. Reddys Lab 1280.45
Cipla 1297.15
Zydus Lifesciences 939.15
Lupin 2274.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×